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1. 
APOPTOTIC AND ANT-TUMIORACTIVITIES 
OF METALLO-SALENS 
CROSS-REFERENCE TO RELATED 
APPLICATIONS 
This application claims benefit of U.S. Provisional Appli 
cations No. 61/075,378 and 61/163,575 filed on Jun. 25, 
2008, and Mar. 26, 2009, respectively which are incorporated 
herein by reference in their entirety. 
TECHNICAL FIELD OF THE INVENTION 
The present invention relates in general to the field of 
metallo-Salens and metallo-Salen derivatives, and more par 
ticularly to the synthesis of Mn(III)- and Fe(III)-salen deriva 
tives and their effects on human cancer and non-cancer cells. 




MATERIALS FILED ON COMPACT DISC 
None. 
BACKGROUND OF THE INVENTION 
Without limiting the scope of the invention, its background 
is described in connection with the use of metallo-salens and 
metallo-Salen derivatives as potential therapeutic agents. 
U.S. Pat. No. 7,122,537 issued to Malfroy-camine and 
Doctrow (2006) describes antioxidant cyclic salen-metal 
compounds. The 537 patent describes compositions of such 
antioxidant cyclic salen-metal compounds having Superoxide 
activity, catalase activity and/or peroxidase activity and meth 
ods of using Such antioxidant cyclic Salen-metal composi 
tions to treat or prevent a disease associated with cell or tissue 
damage produced by free radicals, such as Superoxide. 
United States Patent Application No. 20070142462 
(Kennedy, 2007) discloses methods for treating cancer 
including administering a patient needing treatment a thera 
peutically effective amount of one or more antioxidants 
selected from the group of catalase, N-acetylcysteine, glu 
tathione peroxidase, salen-transition metal complexes, dicu 
marol, and derivatives thereof. 
United States Patent Application No. 20070275944 
(Sharpe, 2007) relates to compounds and compositions to 
treat some neurodegenerative diseases. In some embodi 
ments, the invention relates to an antioxidant comprising a 
Selenium atom and nitroxide group. In further embodiments, 
the antioxidant comprises peroxidase and Superoxide dismu 
tase activity. In some embodiments, the antioxidants are 
effective in treating neurodegenerative diseases including, 
but not limited to, Alzheimer's disease, Parkinson's disease, 
or multiple Sclerosis. In additional embodiments, the inven 
tion relates to using compounds disclosed herein as free radi 
cal electromagnetic imaging agents. 
SUMMARY OF THE INVENTION 
The present invention describes the synthesis, the bio 
chemical activities, and the uses of metallo-Salens and their 
derivatives as anti-tumor agents. The Mn(III)-salen and 













viability, induce strong apoptotic activity, cause nuclear con 
densation, fragmentation, and ultimately death in breast can 
cer cells MCF-7. 
In one embodiment the present invention describes a com 
pound (I) having formula, 
(I) 
wherein the Z is selected from a group comprising—(CH), 
phenyl, naphthyl, —CH2), —C(CH2), and benzoic acid, M 
is a metal selected from a group comprising Fe, Mn, Cu, Ni, 
Hg, Pt.Sc,Ti,V, Cr, Co., Zn, Y, Zr, Nb, Mo, Tc, Ru, Rh, Pd, Ag, 
Cd, Lu, Hf, Ta, W. Re, Os, Ir, Pt, and Au, R. and Rare 
independently selected from a hydrogen, a hydroxyl group 
and a methoxy group, R and Ra'are independently selected 
from a hydrogen, a hydroxyl group and a methoxy group. Rs 
and Rs' are independently selected from a hydrogen, a 
hydroxyl group and a methoxy group, and R and Re" are 
hydrogens. 
In one aspect the Z is selected from a group comprising 
—(CH), —CH), and —(CH), M is Mn, Mn(II). 
Mn(III), Fe, Fe(II) or Fe(II), R and Rare hydroxyl groups, 
and R. R. Rs, and Rs' are hydrogens. In another aspect the 
Z is selected from a group comprising —(CH), —(CH), 
and -(CH), M is Mn, Mn(II), Mn(III), Fe, Fe(II) or Fe(III), 
Ra and Rare hydroxyl groups, and R. R. Rs and Rs are 
hydrogens. In yet another aspect the Z is selected from a 
group comprising —(CH), —(CH), and —(CH), M is 
Mn, Mn(II), Mn(III), Fe, Fe(II) or Fe(III), Rs and Rs' are 
hydroxyl groups, and R. R. R. and Rare hydrogens. 
In one aspect the Z is selected from a group comprising 
—(CH2), —(CH), and —(CH), M is Mn, Mn(II), 
Mn(III), Fe, Fe(II) or Fe(III), R and Rare methoxy groups, 
and R. R. Rs, and Rs' are hydrogens. In another aspect the 
Z is selected from a group comprising —(CH2), —(CH), 
and -(CH), M is Mn, Mn(II), Mn(III), Fe, Fe(II) or Fe(III), 
Ra and Rare methoxy groups, and R. R. Rs, and Rs' are 
hydrogens. In yet another aspect Z is selected from a group 
comprising —(CH), —(CH), and —(CH), M is Mn, 
Mn(II), Mn(III), Fe, Fe(II) or Fe(III), R and Rare methoxy 
groups, and Rs. Rs', Ra, and Rare hydrogens. 
In one aspect the Z is selected from a group comprising 
phenyl, naphthyl, and benzoic acid, M is Mn, Mn(II), Mn(III), 
Fe, Fe(II) or Fe(III), R and Rare hydroxyl groups, and Ra, 
R. Rs, and Rs are hydrogens. In another aspect the Z is 
selected from a group comprising phenyl, naphthyl, and ben 
zoic acid, M is Mn, Mn(II), Mn(III), Fe, Fe(II) or Fe(III), R. 
and Ra' are hydroxyl groups, and R. R. Rs, and Rs' are 
hydrogens. In yet another aspect the Z is selected from a 
group comprising phenyl, naphthyl, and benzoic acid, M is 
Mn, Mn(II), Mn(III), Fe, Fe(II) or Fe(III), Rs and Rs' are 
hydroxyl groups, and R. R. R. and R are hydrogens. 
In one aspect the Z is selected from a group comprising 
phenyl, naphthyl, and benzoic acid, M is Mn, Mn(II), Mn(III), 
Fe, Fe(II) or Fe(III), R and Rare methoxy groups, and Ra, 
Ra', Rs, and Rs' are hydrogens. In another aspect the Z is 
selected from a group comprising phenyl, naphthyl, and ben 
zoic acid, M is Mn, Mn(II), Mn(III), Fe, Fe(II) or Fe(III), R. 
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and Ra' are methoxy groups, and R. R. Rs, and Rs' are 
hydrogens. In yet another aspect Z is selected from a group 
comprising phenyl, naphthyl, and benzoic acid, M is Mn, 
Mn(II), Mn(III), Fe, Fe(II) or Fe(III), Rs and Rs are methoxy 
groups, and R. R. R. and Rare hydrogens. 
In another embodiment the present invention describes a 
method of synthesizing a metallo-Salen compound and its 
derivatives by mixing an aldehyde selected from a group 
comprising salicylaldehyde, 2,3-dihydroxybenzaldehyde, 
2,4-dihydroxybenzaldehyde, 2,5-dihydroxybenzaldehyde, 
2-hydroxy-3-methoxybenzaldehyde, 2-hydroxy-4-methoxy 
benzaldehyde, and 2-hydroxy-5-methoxybenzaldehyde and a 
diamine or a diamino derivative selected from a group com 
prising ethylenediamine, o-phenylenediamine, phenylenedi 
amine, 2,3-diaminonaphthalene, 1,3-diaminobutane, 1,4-di 
aminobutane, and 3,4-diaminobenzoic acid dissolved in an 
organic solvent to form a precipitate. The precipitate formed 
is filtered and washed with the organic solvent. The precipi 
tate is dissolved in the organic solvent and mixed with an 
anhydrous metal dissolved in the organic solvent to form a 
liquid reaction mixture which is heated with stirring to form 
the metallo-Salen compound (I) 
(I) 
wherein, Z is selected from a group comprising —(CH), 
phenyl, naphthyl, —CH2), —CH2), and benzoic acid; M is 
a metal selected from a group comprising Fe, Mn, Cu, Ni, Hg, 
Pt. Sc,Ti,V, Cr, Co., Zn, Y, Zr, Nb, Mo, Tc, Ru, Rh, Pd, Ag, Cd, 
Lu, Hf, Ta, W. Re, Os, Ir, Pt, and Au; R and Rare indepen 
dently selected from a hydrogen, a hydroxyl group and a 
methoxy group; R and Rare independently selected from a 
hydrogen, a hydroxyl group and a methoxy group; Rs and Rs. 
are independently selected from a hydrogen, a hydroxyl 
group and a methoxy group; and R and R are hydrogens. 
The synthesized metallo-Salen compound (I) is precipitated 
by cooling the liquid reaction mixture or by adding diethyl 
ether and isolated by filtration or other physical separation 
method. Finally the isolated metallo-salen compound (I) is 
recrystallized by dissolving in the organic solvent. 
In one aspect of the method of the present invention the 
organic solvent comprises methanol, ethanol, acetone, iso 
propyl alcohol, acetonitrile, benzene, ethyl acetate or any 
combinations thereof. In another aspect the anhydrous metal 
is in the form of a salt, wherein the salt comprises an anion 
selected from a group comprising a chloride, an acetate, a 
halide, a carbonate, a nitrite, a nitrate, a perchlorate, a Sulfate, 
a sulfide, and a hydroxide. 
In yet another embodiment the present invention is a phar 













17N i (I) 
R6 o N/ \ R6 
R5 ^ Y. Rs' 
R4 R3 R R4' 
wherein, Z is selected from a group comprising —(CH), 
phenyl, naphthyl, -CH2), —(CH), and benzoic acid; M is 
a metal selected from a group comprising Fe, Mn, Cu, Ni, Hg, 
Pt.Sc,Ti,V, Cr, Co., Zn, Y, Zr, Nb, Mo, Tc, Ru, Rh, Pd, Ag, Cd, 
Lu, Hf, Ta, W. Re, Os, Ir, Pt, and Au; R and Rare indepen 
dently selected from a hydrogen, a hydroxyl group and a 
methoxy group; R and Rare independently selected from a 
hydrogen, a hydroxyl group and a methoxy group; Rs and Rs' 
are independently selected from a hydrogen, a hydroxyl 
group and a methoxy group; and R and Rare hydrogens. 
In one aspect the composition is effective to treat a cancer, 
selected from a lymphoma, a blastoma, a tumor, a melanoma, 
ovarian cancer, breast cancer, non-Small cell lung cancer, 
Small cell lung cancer, renal cancer, colorectal cancer, pan 
creatic cancer, gastric cancer, bladder cancer, uterine cancer, 
lymphoma, and prostrate cancer. 
In one embodiment the present invention discloses a 
method for treating a cancer in an Subject comprising the 
steps of: (i) identifying a subject in need for treatment against 
the cancer and (ii) providing a therapeutically effective 
amount of a composition sufficient to treat the cancer com 
prising: 
(I) 
wherein, Z is selected from a group comprising —(CH), 
phenyl, naphthyl, -CH2), —(CH), and benzoic acid; M is 
a metal selected from a group comprising Fe, Mn, Cu, Ni, Hg, 
Pt.Sc,Ti,V, Cr, Co., Zn, Y, Zr, Nb, Mo, Tc, Ru, Rh, Pd, Ag, Cd, 
Lu, Hf, Ta, W. Re, Os, Ir, Pt, and Au; R and Rare indepen 
dently selected from a hydrogen, a hydroxyl group and a 
methoxy group; R and Rare independently selected from a 
hydrogen, a hydroxyl group and a methoxy group; Rs and Rs. 
are independently selected from a hydrogen, a hydroxyl 
group and a methoxy group; and R and Rare hydrogens. 
In one aspect of the method of treatment of the present 
invention the cancer comprises a melanoma, ovarian cancer, 
breast cancer, non-Small cell lung cancer, Small cell lung 
cancer, renal cancer, colorectal cancer, pancreatic cancer, 
gastric cancer, bladder cancer, uterine cancer, lymphoma, and 
prostrate cancer. 
BRIEF DESCRIPTION OF THE DRAWINGS 
For a more complete understanding of the features and 
advantages of the present invention, reference is now made to 
the detailed description of the invention along with the 
accompanying figures and in which: 
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FIG. 1 shows the structures of Mn(III)-salen, Fe(III)-salen 
and their derivatives (compounds 1-45) of the present inven 
tion; 
FIG. 2 shows the effect of Mn(III)-salen, Fe(III)-salen and 
their derivatives on cell viability. (A-F): MCF-7 cells were 
treated with 20 uM metallo-salens and incubated for varying 
time periods (24-96 hrs). Viable cells were quantified using 
MTT assay. The percent viable cells (relative to control, 
treated with equivalent amount of DMSO) were plotted as a 
function of time for each compound. This experiment was 
repeated twice with 8 replicate treatments each time. Bars 
indicates standard errors of mean (SEM). Curves 1-42 in 
FIGS. 2A-2F, represent the viability curves for compounds 
1-42 respectively. (A-F") DIC images of the corresponding 
MCF-7 cells that were treated with DMSO (control panel), or 
with 20 uMMn(III)- and Fe(III)-salen complexes for 72 hrs 
showing the visual effects on cellular morphology and 
growth/death. Numbers on each panel represent the corre 
sponding complexes as shown in FIG. 1; 
FIG.3 shows ICso measurements for Mn(III)- and (Fe(III)- 
salen and their derivatives on MCF-7 cells. Approximately 
10,000 cells were grown in each well of a 96 well microtiter 
plate for 24 hrs and then treated with varying concentrations 
(0.05 to 60 uM) of metallo-salens for 96 hrs. Viable cells at 
different concentrations of metallo-salen treatment were 
quantified using MTT assay. The percent viable cells (relative 
to control DMSO treated) were plotted against concentration 
for each compound separately. The concentration of the 
metal-complexes at which the conversion of MTT to forma 
Zan by viable cells is reduced by 50% compared to control 
cells is defined as the ICs. Curves 1-42 in FIGS. 3A-3F 
represent cytotoxicity curves for corresponding metal com 
plexes 1-42 respectively; 
FIG. 4 shows the ICs values for Mn(III)- and Fe(III)-salen 
derivatives toward different cancer and normal cell lines. ICso 
values for each biochemically compounds were determined 
using MTT assay in three different cell lines that include 
MCF-7 (breast cancer), CCL228 (colon cancer) and MCF-10 
(normal breast epithelial cells). ICso values were for compari 
son for each compound (compounds 1-45) as marked. The 
results for the inactive compounds are not shown in the figure; 
FIG. 5 shows the Effect of Mn(III)- and Fe(III)-salen 
derivatives on nuclear integrity (DAPI staining). MCF-7 
cells, grown on a cover glass in a 60 mm culture plate for 24 
hrs, were treated alone or with 100 uM metallo-salens sepa 
rately for 24 hrs, fixed with formaldehyde, stained with DAPI 
followed by visualization under fluorescence microscope. 
Control panel indicates cells that were treated with DMSO. 
Panels 1-42 represent cells treated with compounds 1-42 
respectively; 
FIG. 6 shows the Cytochrome-c translocation induced by 
Mn(II)- and Fe(III)-salen derivatives. MCF-7 cells were 
seeded onto a cover glass for 24 hrs, treated with 100 uM 
metallo-salens and incubated for additional 16 hrs. Cells were 
fixed with formaldehyde, immuno-stained with anti-cyto 
chrome c and FITC conjugated secondary antibodies and 
visualized under fluorescence microscope (left panels). The 
corresponding cell nucleus was visualized by DAPI staining 
(right panels). Control panels: cell treated with DMSO: Pan 
els 1-42 represent cells that were treated with compounds 
1-42 respectively; 
FIG. 7 shows the Mn (III) and Fe(III)-salen derivatives 
(compounds 1-42) activate caspase-3/7. CCL228 (human 
colon cancer) cells were treated with 100 uM metallo-salen 
derivatives for 16 hand subjected to caspase 3/7 activation 
assay using a commercially available caspase-3/7 Assay Kit 













to the untreated control) was plotted for different metallo 
salen derivatives. Bars indicated SEM; 
FIG.8 shows the regression of tumor xenograft by Mn(III)- 
salen complexes (compounds 6, 9 and 16). Athymic nude 
nu/nu mice carrying the colon cancer Xenograft were admin 
istered with 10 mg/kg of 3,3'-dimethoxy Mn(III)-salen (com 
pound 6), 3,3'-dihydroxy Mn(III)-salphen (compound 9) and 
3,3'-dihydroxy Mn(III)-salnaphen (compound 16) at 4 days 
interval, for over a period of 21 days. Tumor diameters were 
measured using a slide caliper prior to each administration 
and plotted (left panel). Bar indicated standard deviation (3 
replicate experiments). Right panel shows the pictures of the 
treated and control mouse at different time points; and 
FIGS. 9A and 9B show some additional metallo-salen 
complexes with different attached substituents. 
DETAILED DESCRIPTION OF THE INVENTION 
While the making and using of various embodiments of the 
present invention are discussed in detail below, it should be 
appreciated that the present invention provides many appli 
cable inventive concepts that can be embodied in a wide 
variety of specific contexts. The specific embodiments dis 
cussed herein are merely illustrative of specific ways to make 
and use the invention and do not delimit the scope of the 
invention. 
To facilitate the understanding of this invention, a number 
of terms are defined below. Terms defined herein have mean 
ings as commonly understood by a person of ordinary skill in 
the areas relevant to the present invention. Terms such as “a”, 
“an and “the are not intended to refer to only a singular 
entity, but include the general class of which a specific 
example may be used for illustration. The terminology herein 
is used to describe specific embodiments of the invention, but 
their usage does not delimit the invention, except as outlined 
in the claims. 
The present invention describes the biochemical activities 
of metallo-Salen and the development novel anti-tumor 
agents. The inventors synthesized 45 different derivatives of 
Mn(III)-salen and Fe(III)-salen with different substituents 
and bridging spacer groups in the Salen ligand and analyzed 
their apoptotic activities toward different cancer (breast and 
colon) and normal cells (breast epithelial cells). The results 
demonstrated that several Mn(III)- and Fe(III)-salen deriva 
tives affect cell viability and induced strong apoptotic activity 
toward breast cancer cells MCF-7. Treatment with biochemi 
cally active Mn(III)- and Fe(III)-salen derivatives for 24 hrs 
resulted in nuclear condensation (intense DAPI staining), 
fragmentation and ultimately death in MCF-7 cells. The 
nuclear condensation and fragmentation are indications of 
apoptotic pathway of cell death. Moreover, each of these 
active compounds induced release of cytochrome c from the 
mitochondria to cytosol Suggesting the involvement of mito 
chondrial pathway of apoptosis. 
The present invention analyzed and describes the bio 
chemical and antitumor activities of metallo-Salen complexes 
in cancer cells. Notably, metallo-salens, due to their diverse 
electronic and structural features show varying spectrum of 
chemical reactivities and have been extensively used for cata 
lyzing organic reactions'. Metallo-salens are also very well 
studied class of chemical nucleases that bind, cleave, and 
damage nucleic acids’. Iron and copper based metallo 
salen complexes has been shown to produce reactive oxygen 
species under reducing environment that damage DNA in a 
sequence neutral fashion in vitro and have been applied for 
studying drug-DNA interaction and foot-printing’. 
Mn(III)-Salen complexes are shown to posses Superoxide dis 
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mutase (SOD) and catalase activities and are considered as 
synthetic SOD mimics'. Recent studies by the present 
inventors have demonstrated that Fe(III)-salen induces apo 
ptosis in human embryonic kidney (HEK293) cells. 
Apoptosis is a highly orchestrated cell Suicidal program 5 
required to maintain a balance between cell proliferation and 
death. Apoptosis is usually induced by a variety of physi 
ological and external stimuli. Most of the anticancer agents 
irrespective of their mechanism of action induce apoptosis in 
cancer cells. Cis-diaminodichloro-platinum(II) (cisplatin) 10 
and cis-diamine (cyclobutane-1,1-dicarboxylato) platinum 
(II) (carboplatin) are the first transition metal based antitumor 
drugs in clinical use, Since then many other transition 
metal complexes as well as Small molecule based antitumor 
agents have been developed and are in clinical trial’’. 
While the platinum based antitumor agents have enormous 
impact on current cancer therapy, the types of cancer that can 
be treated with platinum agents are narrow and suffer from 
side effects and resistance phenomena'. In order to over 
come clinical problems associated with the relatively limited 20 
activity of platinum based agents against the broad spectrum 
of human malignancies, acquired resistance, and side effects, 
novel non-platinum metal-based anticancer complexes have 
been and are being developed'. 
Recent advances in understanding the biochemical roles of 25 
metal ions and metal complexes and their medicinal applica 
tion demonstrated significant prospects for the development 
of metal complexes as drugs. O'''''7'''2'-9. The 
anticancer and anti-metastatic properties of platinum and 
ruthenium complexes have been well established and many of 30 
these metal-complexes are under intensive pre-clinical and 
clinical investigations. However, in spite of their great activi 
ties toward certain types of cancers cells, many of these 
metal-complexes are toxic to normal tissues”. In addition, 
several types of cancer cells are resistant to those compounds. 35 
Therefore understanding biochemical effects of new and 
known molecules and developing new biochemically active 
molecules inducing apoptosis in cancer cells is important for 
discovering effective anticancer drugs'. 
Herein, in order to explore the biochemical activities of 40 
metallo-Salen and also to develop novel anti-tumor agents, we 
synthesized 45 different derivatives of Mn(III)-salen and 
Fe(III)-salen with different substituents and bridging spacer 
groups in the salen ligand and analyzed their apoptotic activi 
ties toward different cancer (breast and colon) and normal 45 
cells (breast epithelial cells). Our results demonstrated that 
several Mn(III)- and Fe(III)-salen derivatives affect cell 
viability and induced strong apoptotic activity toward breast 
cancer cells MCF-7. Treatment with biochemically active 
Mn(III)- and Fe(III)-salen derivatives for 24 hrs resulted in 50 
nuclear condensation (intense DAPI staining), fragmentation 
and ultimately death in MCF-7 cells. The nuclear condensa 
tion and fragmentation are indications of apoptotic pathway 
of cell death. Moreover, each of these active compounds 
induced release of cytochrome c from the mitochondria to 55 
cytosol Suggesting the involvement of mitochondrial path 
way of apoptosis. 
The nature of the Substitutents, bridging spacers and also 
the central metal-ion played key roles in determining the 
apoptotic activities and efficiencies of the metallo-Salen 60 
derivatives of the present invention. The changes in the eth 
ylenediamine bridge to o-phenylene diamine or o naphtha 
lene diamine increased efficiencies of the apoptotic activities 
of both the Mn(III)- and Fe(III)-salen derivatives of the 
present invention due to the enhanced interaction between 65 
more aromatic salen complexes with DNA. In general, the 
methoxy substituted metallo-salens were more active than 
15 
8 
hydroxy Substituted metallo-Salens with some exceptions. 
This is attributed to the enhanced permeability through cell 
membrane. The increase in spacer from ethylenediamine to 
1,4-diaminobutane in the Salen ligand diminished the apop 
tosis activity of Fe(III)-Salen. The changes in spacing 
between the dimino group of the Salen ligand, increased the 
flexibility of the metallo-salen complex from nearly planer 
structure (of Fe(III)-salen) to non-planer three dimensional 
structure that may perturb physical interaction with nucleic 
acids and proteins which may have been reflected in the 
apoptotic activity'. 
The ICs values for the active Mn(III)-salen complexes of 
the present invention ranged from 12 to 55 uM and Fe(III)- 
salen complexes 220 nM to 22 uM towards the MCF7 cells, 
respectively. Most importantly, most of the active Mn(III)- 
salen derivatives showed 2-5 five fold selectivity in killing 
cancer cells (MCF-7 and CCL228) over normal cells (breast 
epithelial cells MCF-10) providing further proof of their 
potential application as novel anti-tumor agents. The nano 
molar ranges of ICs values for the selective Fe(III)-com 
plexes of the present invention indicate their effectiveness in 
killing cells. The ICs value for cis-platin in MCF-7 cells is 
measured to be ~20 uM which suggest that Mn(III)- and 
Fe(III)- are comparable or even more effective in inducing 
cell death in vitro. 
The inventors also studied the in vivo efficacy of the 
selected Mn(III)-salen complexes 3,3'-dimethoxy Mn(III)- 
salen (compound 6), 3,3'-dihydroxy Mn(III)-salphen (com 
pound 9) and 3,3'-dihydroxy Mn(III)-salnaphen (compound 
16) using colon cancer Xenograft. Application of the com 
pounds 6 and 9 (3,3'-dimethoxy Mn(III)-salen and 3,3'-dihy 
droxy Mn(III)-salphen respectively) resulted in complete 
arrest of tumor growth in vivo in colon cancer Xenograft. 
These results demonstrated that compounds 6 and 9 have 
antitumor activity in vivo. 
The present inventors have synthesized several Mn(III)- 
salen and Fe(III)-salen derivatives (compounds 1-45, FIG. 1) 
and investigated their biochemical effects on human breast 
cancer cells MCF-7, colon cancer cells CCL228 and non 
malignant breast epithelial cells MCF-10. We showed that 
Mn(III)-salen and Fe(III)-salen derivatives affect cell viabil 
ity and induce apoptosis in MCF-7 cells at nano to micro 
molar concentration range. Importantly, most of the Mn(III)- 
salen derivatives and selected Fe(III)-salen derivative exhib 
ited cancer cell selective apoptosis demonstrating their strong 
potential as novel antitumor agents. Mechanistic Studies Sug 
gest that metallo-Salens induce oxidative stress and activate 
mitochondrial pathway of apoptosis. 
Reagents and Chemicals: All reagents for organic synthe 
sis and buffers were purchased from Sigma-Aldrich unless 
otherwise noted. Tissue culture medium DMEM (Dulbecco's 
Modified Eagle's Medium), FBS (Fetal Bovine Serum), peni 
cillin and streptomycin were purchased from Sigma-Aldrich. 
Ferric chloride (anhydrous) was purchased from Spectrum 
Chemical Manufacturing Corporation. Anti-cytochrome-c 
(monoclonal) antibody was purchased from Upstate Biotech, 
and FITC conjugated anti-mouse secondary antibody was 
obtained from Jackson Immunoresearch Laboratory. DAPI 
(4,6-diamidino-2-phenylindole) and anti-actin (monoclonal) 
were obtained from Chemicon. MTT (3-(4,5-dimethylthiaz 
olyl-2)-2,5-diphenyltetrazolium bromide) was obtained from 
Tokyo Chemical Industry Co. MCF-7, MCF-10 and CCL228 
cell lines were obtained from ATCC (AmericanType Culture 
Collection). 
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Synthesis of Mn(III)- and Fe(III)-salen and their Deriva 
tives (Compounds. 1-45) 
Mn(III)- and Fe(III)-salen derivatives were synthesized 
and characterized following a general procedure as described 
previously 7. In brief, salen ligands were synthesized by 
mixing two equivalents of salicylaldehyde (or derivatives) 
with one equivalent of ethylenediamine in methanol at room 
temperature that resulted in yellow or orange colored precipi 
tate of respective salens. The precipitate was filtered and 
washed with cold methanol. Each of the ligand was charac 
terized by NMR and/or elemental analysis. Results are con 
sistent with their structures. In order to analyze the biochemi 
cal activities of Mn(III)- and Fe(III)-salen derivatives, the 
inventors synthesized several salen derivatives by changing 
the spacer between dimino groups and introducing hydroxy 
and methoxy Substituents in the salen ligand using a general 
procedure (FIG. 1). For the synthesis of Mn(III)- and 
Fe(III)-salen derivatives, the respective salen ligand deriva 
tives were dissolved in methanol and then mixed with equiva 
lent amount of anhydrous Mn(III) acetate or Fe(III) chloride 
in methanol and heated to 60°C. with continuous stirring for 
30 min. This resulted in a dark brown/black solution that was 
cooled down to room temperature. In most cases the metal 
complexes were precipitated out upon cooling the reaction 
mixtures. In some cases the metal complexes were precipi 
tated by adding diethyl ether into the cold reaction mixtures. 
The products were isolated, recrystallized from methanol 
characterized and analyzed by NMR and/or elemental analy 
sis and corresponding Mn(III)- and Fe(III)-salen metal com 
plexes were characterized by mass spectrometry (ESI-MS) 
and/or elemental analysis and the results are consistent with 
the proposed structures. 
Mn(III)-salen acetate (compound 1), Mn(III)-salphen 
acetate (compound 8) and Mn(III)-salnaphen acetate (com 
pound 15) were synthesized and characterized as described 
previously and Fe(III)-salen chloride (compound 22): 
These two compounds were synthesized and characterized as 
previously reported. 
3,3'-Dihydroxysalen Mn(III) acetate (2): Two equivalents 
of 2,3-dihydroxybenzaldehyde (1 g, 7.2 mmol) was mixed 
with one equivalent of ethylenediamine (0.21 g, 3.5 mmol) in 
methanol that resulted in orange precipitate of 3,3'-dihydrox 
ysalen (L2). L2 (600 mg, 2 mmol) was complexed with one 
equivalent of Mn(III) acetate (562 mg, 2.1 mmol) to obtain 
compound 2 (40% yield). Observed m/z value for 3,3'-dihy 
droxysalen Mn(II) acetate: 353.27 (M+, OAc); CHN 
analysis for 3,3'-dihydroxysalen Mn(III) acetate: Calculated 
(for CH-NOMn. 1.0HO) C: 50.24%, H, 4.50%, N, 
6.50%. Observed: C: 50.52%, H, 4.76%, N, 6.34%. 
4,4'-Dihydroxysalen Mn(III) acetate (3): Two equivalents 
of 2,4-dihydroxybenzaldehyde (1.38 g. 10 mmol) was mixed 
with one equivalent of ethylenediamine (0.3 g 5 mmol) in 
methanol that resulted in light orange precipitate of 4,4'- 
dihydroxysalen (L3). This ligand (600 mg, 2 mmol) was 
complexed with one equivalent of Mn(III) acetate (562 mg, 2 
mmol) to obtain compound 3 (45% yield). Observed m/z. 
value for 4,4'-Dihydroxysalen Mn(III) acetate: 353.27 (M--, 
—OAc). CHN analysis: Calculated (for CH7NOMn. 
1.OH2O) C: 50.24%, H, 4.50%, N, 6.50%. Observed: C: 
50.48%, H, 4.6%, N, 6.43%. 
5,5-Dihydroxysalen Mn(III) acetate (4): Two equivalents 
of 2,5-dihydroxybenzaldehyde (1.38 g. 10 mmol) was mixed 
with one equivalent of ethylenediamine (0.3 g 5 mmol) in 
methanol that resulted in reddish brown precipitate of 5,5'- 
dihydroxysalen (L4). This ligand (600 mg, 2 mmol) was 
complexed with one equivalent of Mn(III) acetate (562 mg, 2 













value for 5,5-Dihydroxysalen Mn(III) acetate: 353.27 (M+, 
—OAc). CHN analysis: Calculated (for C.H.N.O.Mn. 
0.4HO) C: 51.53%, H, 4.28%, N, 6.64%. Observed: C: 
51.52%, H, 4.53%, N, 6.82%. 
3,3'-Dimethoxysalen Mn(III) acetate (5): Two equivalents 
of 2-hydroxy-3-methoxybenzaldehyde (1.52 g, 10 mmol) 
was mixed with one equivalent of ethylenediamine (0.3 g, 5 
mmol) in methanol that resulted in bright yellow precipitate 
of 3,3'-dimethoxysalen ligand (L5). This ligand (65.6 mg, 2 
mmol) was complexed with one equivalent of Mn(III) acetate 
(562 mg, 2 mmol) to obtain compound. 5 (58% yield). 
Observed m/z value for 3,3'-Dimethoxysalen Mn(III) acetate: 
381.20 (M+, —OAc). CHN analysis: Calculated (for 
CHNOMn. 3.0HO) C: 48.59%, H, 5.51%, N, 5.66%. 
Observed: C: 48.77%, H, 5.61%, N, 5.54%. 
4,4'-Dimethoxysalen Mn(III) acetate (6): Two equivalents 
of 2-hydroxy-4-methoxybenzaldehyde (1.52 g, 10 mmol) 
was mixed with one equivalent of ethylenediamine (0.3 g, 5 
mmol) in methanol that resulted in orange brown precipitate 
of 4,4'-dimethoxysalen ligand (L6). This ligand (65.6 mg, 2 
mmol) was complexed with one equivalent of Mn(III) acetate 
(562 mg, 2 mmol) to obtain compound. 6 (52% yield). 
Observed m/z value 4,4'-Dimethoxysalen Mn(III) acetate: 
381.20 (M+, —OAc). CHN analysis: Calculated (for 
CHNOMn. 1.0HO) C: 52.41%, H, 5.06%, N, 6.11%. 
Observed: C: 52.52%, H, 5.24%, N, 6.15%. 
5.5'-Dimethoxysalen Mn(III) acetate (7): Two equivalents 
of 2-hydroxy-5-methoxybenzaldehyde (1.52 g, 10 mmol) 
was mixed with one equivalent of ethylenediamine (0.3 g, 5 
mmol) in methanol that resulted in bright yellow precipitate 
of 5,5'-dimethoxysalen (L7). This ligand (656 mg, 2 mmol) 
was complexed with one equivalent of Mn(III) acetate (562 
mg, 2 mmol) to obtain compound. 7 (45% yield). Observed 
m/z value for 5.5'-Dimethoxysalen Mn(II) acetate: 381.20 
(M+, —OAc). CHN analysis: Calculated (for 
C20H21N2O6Mn. 0.4 H2O) C: 53.67%, H, 4.91%, N, 
6.26%. Observed: C: 53.65%, H, 5.06%, N, 6.07%. 
3,3'-Dihydroxysalphen Mn(III) acetate (9): Two equiva 
lents of 2,3-dihydroxybenzaldehyde (1.38 g, 10 mmol) was 
mixed with one equivalent of o-phenylenediamine (540 mg, 5 
mmol) in methanol that resulted in red colored precipitate of 
3,3'-dihydroxysalphen (L9). This ligand (700 mg, 2 mmol) 
was complexed with one equivalent of Mn(III) acetate (562 
mg, 2 mmol) to obtain compound. 9 (55% yield). Observed 
m/Z for 3,3'-Dihydroxysalphen Mn(III) acetate: 401.27 (M--, 
—OAc). CHN analysis: Calculated (for CH7NOMn. 
2.7HO) C, 51.92%, H, 4.43%, N, 5.50%. Observed: C: 
51.73%, H, 4.60%, N, 5.55%. 
4,4'-Dihydroxysalphen Mn(III) acetate (10): Two equiva 
lents of 2,4-dihydroxybenzaldehyde (1.38 g, 10 mmol) was 
mixed with one equivalent of o-phenylenediamine (540 mg, 5 
mmol) in methanol that resulted in dark orangered precipitate 
of 4,4'-dihydroxysalen (L10). This ligand (700 mg, 2 mmol) 
was complexed with one equivalent of Mn(III) acetate (562 
mg, 2 mmol) to obtain compound. 10 (60% yield). Observed 
m/Z for 4,4'-dihydroxysalphen Mn(III) acetate: 401.27 (M--, 
—OAc). CHN analysis: Calculated (for CH7NOMn. 
1.5HO) C, 54.22%, H, 4.14%, N, 5.80%. Observed: C: 
53.97%, H, 4.50%, N, 5.53%. 
5.5'-Dihydroxysalphen Mn(III) acetate (11): Two equiva 
lents of 2,5-dihydroxybenzaldehyde (1.38 g, 10 mmol) was 
mixed with one equivalent of ophenylenediamine (540 mg, 5 
mmol) in methanol that resulted in dark reddish brown pre 
cipitate of 5,5-dihydroxysalphen (L11). This ligand (700 mg. 
2 mmol) was complexed with one equivalent of Mn(III) 
acetate (562 mg, 2 mmol) to obtain compound. 11 (45% 
yield). Observed m/z for 5,5-dihydroxysalphen Mn(III) 
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acetate: 401.33 (M--, - OAc). CHN analysis: Calculated (for 
CHNOMn. 2.5H2O) C, 52.29%, H, 4.35%, N, 5.54%. 
Observed: C: 52.43%, H, 4.12%, N, 5.43%. 
3,3'-Dimethoxysalphen Mn(III) acetate (12): Two equiva 
lents of 2-hydroxy-3-methoxybenzaldehyde (1.52 g, 10 
mmol) was mixed with one equivalent of o-phenylenedi 
amine (540 mg, 5 mmol) in methanol that resulted in bright 
orange red precipitate of 3,3'-dimethoxysalen ligand (L12). 
This ligand (752 mg, 2 mmol) was complexed with one 
equivalent of Mn(III) acetate (562 mg, 2 mmol) to obtain 
compound 12 (62% yield). Observed m/z for 3,3'-dimethox 
ysalphen Mn(III) acetate: 429.20 (M', - OAc). CHN analy 
sis: Calculated (for CHNOMn. 1.6H2O) C, 55.73%, H, 
4.72%, N, 5.41%. Observed: C:55.38%, H, 4.95%, N, 5.12%. 
4,4'-Dimethoxysalphen Mn(III) acetate (13): Two equiva 
lents of 2-hydroxy-4-methoxybenzaldehyde (1.52 g, 10 
mmol) was mixed with one equivalent of o-phenylenedi 
amine (540 mg, 5 mmol) in methanol that resulted in bright 
orange precipitate of 4,4'-dimethoxysalen ligand (L13). This 
ligand (752 mg, 2 mmol) was complexed with one equivalent 
of Mn(III) acetate (562 mg, 2 mmol) to obtain compound 13 
(58% yield). Observed m/z for 4,4'-dimethoxysalphen 
Mn(III) acetate: 429.20 (M', - OAc). CHN analysis: Calcu 
lated (for CHNOMn. 1.2H2O) C, 56.52%, H, 4.62%, N, 
5.49%. Observed: C: 56.22%, H, 4.49%, N, 5.25%. 
5,5'-Dimethoxysalphen Mn(III) acetate (14): Two equiva 
lents of 2-hydroxy-5-methoxybenzaldehyde (1.52 g, 10 
mmol) was mixed with one equivalent of o-phenylenedi 
amine (540 mg, 5 mmol) in methanol that resulted in light red 
precipitate of 5,5'-dimethoxysalen (L14). This ligand (752 
mg, 2 mmol) was complexed with one equivalent of Mn(III) 
acetate (562 mg, 2 mmol) to obtain compound 14 (50% 
yield). Observed m/z for 5.5'-dimethoxysalphen Mn(III) 
acetate: 429.20 (M', - OAc). CHN analysis: Calculated (for 
CHNOMn. 0.5H2O) C, 57.96%, H, 4.46%, N, 5.63%. 
Observed: C: 58.39%, H, 4.51%, N, 5.56%. 
3,3'-Dihydroxysalnaphen Mn(III) acetate (compound 16): 
Two equivalents of 2,3-dihydroxybenzaldehyde (2.1 g, 15.2 
mmol) was mixed with one equivalent of 2,3-diaminonaph 
thalene (1.1 g, 6.9 mmol) in methanol that resulted in red 
precipitate of 3,3'-dihydroxysalen (compound L16). This 
ligand was complexed with one equivalent of Mn(III) acetate 
to obtain compound 16. Observed m/z for 3,3'-Dihydroxysal 
naphen Mn(III) acetate: 451.33 (M', - OAc). CHN analysis: 
Calculated (for CHNOMn. 3.0HO) C: 55.33%, H, 
4.46%, N, 4.96%. Observed: C:55.44%, H, 4.35%, N, 4.65%. 
4,4'-Dihydroxysalnaphen Mn(III) acetate (compound 17). 
Two equivalents of 2,4-dihydroxybenzaldehyde (1.8 g. 13 
mmol) was mixed with one equivalent of 2,3-diaminonaph 
thalene (1 g, 6.3 mmol) in methanol that resulted in dark 
orange brown precipitate of 4,4'-dihydroxysalen (L17). This 
ligand (L17) was complexed with one equivalent of Mn(III) 
acetate to obtain compound 17. Observed m/z for 4,4'-Dihy 
droxysalnaphen Mn(III) acetate: 451.33 (M', - OAc). CHN 
analysis: Calculated (for CHNOMn. 1.5H2O) C: 
58.11%, H, 4.13%, N, 5.21%. Observed: C: 58.41%, H, 
3.89%, N, 5.00%. 
5,5-Dihydroxysalnaphen Mn(III) acetate (compound 18). 
Two equivalents of 2,5-dihydroxybenzaldehyde (2 g, 14.5 
mmol) was mixed with one equivalent of 2,3-diaminonaph 
thalene (1.1 g, 6.9 mmol) in methanol that resulted in dark red 
precipitate of 5,5-dihydroxysalen (L18). This ligand (L17) 
was complexed with one equivalent of Mn(III) acetate to 
obtain compound 18. Observed M/Z value for 5,5-dihydroxy 
salnaphen Mn(III) acetate: 451.33 (M', - OAc). CHN analy 
sis: Calculated (for CHNOMn. 2.2H2O) C: 56.77%, H, 













3,3'-Dimethoxysalnaphen Mn(III) acetate (compound 19). 
Two equivalents of 2-hydroxy-3-methoxybenzaldehyde (2.7 
g, 17.5 mmol) was mixed with one equivalent of 2,3-diami 
nonaphthalene (1.2g, 7.6 mmol) in methanol that resulted in 
bright orange precipitate of 3,3'-dimethoxysalen ligand 
(L19). This ligand (L19) was complexed with one equivalent 
of Mn(III) acetate to obtain compound 19. Observed M/Z 
value for 3,3'-dimethoxy salnaphen Mn(III) acetate: 479.27 
(M', - OAc). CHN analysis: Calculated (for 
CHNOMn. 0.5H2O) C: 61.43%, H, 4.42%, N, 5.11%. 
Observed: C: 61.14%, H, 4.78%, N, 5.35%. 
4,4'-Dimethoxysalnaphen Mn(III) acetate (compound 20). 
Two equivalents of 2-hydroxy-4-methoxybenzaldehyde (2.1 
g, 13.8 mmol) was mixed with one equivalent of 2,3-diami 
nonaphthalene (1 g, 6.3 mmol) in methanol that resulted in 
orange colored precipitate of 4, 4'-dimethoxySalen (L20). 
This ligand (L20) was complexed with one equivalent of 
Mn(III) acetate to obtain compound 20. Observed m/z value 
for 4,4'-dimethoxy salnaphen Mn(III) acetate: 479.27 (M', 
—OAc). CHN analysis Calculated (for CHNOMn. 
4.0H2O) C: 55.09%, H, 5.12%, N, 4.59%. Observed: C: 
54.56%, H, 4.59%, N, 4.86%. 
5.5'-Dimethoxysalnaphen Mn(III) acetate (compound 21). 
Two equivalents of 2-hydroxy-5-methoxybenzaldehyde 
(2.89 g, 19 mmol) was mixed with one equivalent of 2,3- 
diaminonaphthalene (1.5 g., 9.5 mmol) in methanol that 
resulted in dark reddish brown precipitate of 5,5'-dimethox 
ySalen (L21). This ligand (L21) was complexed with one 
equivalent of Mn(III) acetate to obtain compound 21. 
Observed m/z value for 5.5'-dimethoxy salnaphen Mn(III) 
acetate: 479.27 (M', - OAc). CHN analysis: Calculated (for 
CHNOMn. 1.2HO) C: 60.05%, H, 4.57%, N, 5.00%. 
Observed: C: 60.04%, H, 4.56%, N, 5.35%. 
3,3'-Dihydroxysalen Fe(III) chloride (compound 23): The 
ligand 3,3'-dihydroxysalen (L2) was complexed with one 
equivalent Fe(III) chloride to obtain compound 23. Observed 
m/z value for 3,3'-Dihydroxysalen Fe(III) chloride (com 
pound 23): 354.20 (M', -Cl). CHN analysis: Calculated (for 
CHNOFeCl. 1.5HO)C: 46.13%, H, 4.11%, N, 6.72%. 
Observed: C: 46.32%, H, 4.22%, N, 6.85%. 
4,4'-Dihydroxysalen Fe(III) chloride (compound 24): The 
ligand 4,4'-dihydroxySalen (L3) was complexed with one 
equivalent of Fe(III) chloride to obtain compound 24. 
Observed m/z value for 4,4'-dihydroxysalen Fe(III) chloride: 
354.20 (M', -Cl). CHN analysis: Calculated (for 
CHNOLFeC1. 0.5HO)C:48.21%, H, 3.78%, N, 7.03%. 
Observed: C: 48.11%, H, 4.08%, N, 6.98%. 
5.5'-Dihydroxysalen Fe(III) chloride (compound 25): The 
ligand 5.5'-dihydroxysalen (L4) was complexed with one 
equivalent Fe(III) chloride to obtain compound 25. Observed 
m/z value for 5.5'-dihydroxysalen Fe(III) chloride (com 
pound 25): 354.20 (M', -Cl). CHN analysis: Calculated (for 
CHNOFeCl. 2.4HO)C:44.39%, H, 4.38%, N, 6.47%. 
Observed: C: 44.16%, H, 4.33%, N, 6.62%. 
3,3'-Dimethoxysalen Fe(III) chloride (26): The ligand 3,3'- 
dimethoxysalen (L5) was complexed with one equivalent 
Fe(III) chloride to obtain compound 26. Observed m/z: 
382.20 (M', -Cl). CHN analysis (Calculated for 
CHNOFeCI) C: 51.89%, H, 4.35%, N, 6.72%. 
Observed: C: 52.15%, H, 4.58%, N, 6.93%. 
4,4'-Dimethoxysalen Fe(III) chloride (27): The ligand 4,4'- 
dimethoxysalen (L6) was complexed with one equivalent 
Fe(III) chloride to obtain compound 27. Observed m/z value: 
382.20 (M', -Cl). CHN analysis (Calculated for 
C.H.N.O. FeCl. 1.3H2O)C: 49.02%, H, 4.71%, N, 6.35%. 
Observed: C: 48.64%, H, 4.46%, N, 6.81%. 
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5,5'-Dimethoxysalen Fe(III) chloride (28): The ligand 5,5'- 
dimethoxysalen (L7) was complexed with one equivalent of 
Fe(III) chloride to obtain compound 28. Observed m/z value 
382.20 (M', -Cl). CHN analysis: Calculated (for 
C.H.N.O. FeC1. 0.2H2O)C:51.32%, H, 4.40%, N, 6.65%. 
Observed: C: 51.06%, H, 4.53%, N, 6.88%. 
Fe(III)-salphen.chloride (compound 29). Two equivalents 
of salicylaldehyde (2.2g, 18.1 mmol) was mixed with one 
equivalent of o-phenylenediamine (920 mg, 8.4 mmol) in 
methanol that resulted in light orange precipitate of salphen 
ligand (L8). This ligand (500 mg, 1.6 mmol) was complexed 
with one equivalent of Fe(III) chloride (295 mg, 1.8 mmol) to 
obtain compound 29 (65% yield). Observed m/z value for 
compound 29: 370.18 (M', -Cl). CHN analysis: Calculated 
(for CHNOFeCl. 2.5H2O) C: 53.37%, H, 4.26%, N, 
6.22%. Observed: C: 53.32%, H, 3.88%, N, 6.00%. 
3,3'-Dihydroxysalphen Fe(III) chloride (30): The ligand 
3,3'-dihydroxysalphen (L9) was complexed with one equiva 
lent Fe(III) chloride to obtain compound 30. CHN analysis 
for compound 30 Calculated (for CHNOFeCl. 2.7H2O) 
C, 49.40%, H, 4.02%, N, 5.76%. Observed: C: 49.08%, H, 
3.63%, N, 5.76%. 
4,4'-Dihydroxysalphen Fe(III) chloride (compound 31): 
The ligand 4,4'-dihydroxysalen (L10) was complexed with 
one equivalent Fe(III) chloride to obtain compound 31. CHN 
analysis for 4,4'-dihydroxysalphen Fe(III) chloride (com 
pound 31) Calculated (for CHNOFeCl. 1.8HO) C, 
51.17%, H, 3.78%, N, 5.97%. Observed: C: 51.53%, H, 
4.28%, N, 5.57%. 
5,5-Dihydroxysalphen Fe(III) chloride (compound 32): 
The ligand 5,5'-dihydroxysalphen (L11) was complexed with 
one equivalent of Fe(III) chloride to obtain compound 32. 
CHN analysis for 5,5-dihydroxysalphen Fe(III) chloride 
(compound 32) Calculated (for CHNOFeCl. 1.7H2O) 
C, 51.30%, H, 3.75%, N, 5.98%. Observed: C: 51.28%, H, 
3.77%, N, 5.62%. 
3,3'-Dimethoxysalphen Fe(III) chloride (compound 33): 
The ligand 3,3'-dimethoxysalen (L12) was complexed with 
one equivalent Fe(III) chloride to obtain compound 33. CHN 
analysis for 3,3'-dimethoxysalphen Fe(III) chloride (com 
pound 33) Calculated (for CHNOFeCl. 3H2O) C, 
50.89%, H, 4.66%, N, 5.39%. Observed: C: 50.63%, H, 4.0%, 
N, 5.28%. 
4,4'-Dimethoxysalphen Fe(III) chloride (compound 34): 
The ligand 4,4'-dimethoxysalen (L13) was complexed with 
one equivalent Fe(III) chloride to obtain compound 34. CHN 
analysis for 4,4'-dimethoxysalphen Fe(III) chloride (com 
pound 34) Calculated (for CHNOFeCl) C, 56.74%, H, 
3.89%, N, 6.01%. Observed: C:56.62%, H, 4.04%, N, 6.02%. 
5,5'-Dimethoxysalphen Fe(III) chloride (compound 35): 
The ligand 5.5'-dimethoxysalen (L14) was complexed with 
one equivalent of Fe(III) chloride to obtain compound 35. 
CHN analysis 35: Calculated (for CHNOFeCI) C. 
56.74%, H, 3.89%, N, 6.01%. Observed: C:56.2%, H, 4.08%, 
N, 5.93%. 
Fe(III)-salnaphen chloride (compound 36): Two equiva 
lents of salicylaldehyde (2.1 g, 17.2 mmol) was mixed with 
one equivalent of 2,3-diaminonaphthalene (1.3 g, 8.2 mmol) 
in methanol that resulted in dark yellowish orange precipitate 
of Salnaphen (L15). This ligand (450 mg, 1.23 mmol) was 
complexed with one equivalent of Fe(III) chloride (226 mg, 
1.4 mmol) to obtain 36 (60% yield). Observed M/Z value for 
compound 36: 420.24 (M', - Cl); CHN analysis for 36: 
Calculated (for CHNOFeCl. 1.5H2O) C: 59.80%, H, 
3.97%, N, 5.81%. Observed: C: 60.05%, H, 3.96%, N, 5.78%. 
3,3'-Dihydroxysalnaphen Fe(III) chloride (compound 37): 













was complexed with one equivalent of Fe(III) chloride (138 
mg, 0.85 mmol) to obtain compound 37 (45% yield). 
Observed m/z value for compound 37: 452.27 (M', -Cl). 
CHN analysis: Calculated (for CHNOFeC1.2H2O) C: 
55.04%, H, 3.85%, N, 5.35%. Observed: C: 55.42%, H, 
3.59%, N, 5.36%. 
4,4'-Dihydroxysalnaphen Fe(III) chloride (compound 38): 
The ligand 4,4'-dihydroxysalen (L17,450 mg, 1.3 mmol) was 
complexed with one equivalent of Fe(III) chloride (243 mg, 
1.5 mmol) to obtain compound 38 (48% yield). Observed m/z. 
value for compound 38: 452.27 (M', -Cl). CHN analysis: 
Calculated (for CHNOLFeCl. 4HO) C: 51.50%, H, 
4.32%, N, 5.00%. Observed: C: 51.10%, H, 4.04%, N, 4.96%. 
5.5'-Dihydroxysalnaphen Fe(III) chloride (compound 39): 
The ligand 5.5'-dihydroxysalen (L18, 450 mg, 1.36 mmol) 
was complexed with one equivalent of Fe(III) chloride (235 
mg, 1.4 mmol) to obtain compound 39 (52% yield). Observed 
m/z value for compound 39: 452.27 (M', -Cl). CHN analy 
sis: Calculated (for CHNOFeCl. 3.5H2O) C: 52.35%, 
H, 4.21%, N, 5.09%. Observed: C: 52.70%, H, 4.07%, N, 
5.01%. 
3,3'-DimethoxysalnaphenFe(III) chloride (compound 40): 
The ligand 3,3'-dimethoxysalen ligand (L19, 410 mg. 0.96 
mmol) was complexed with one equivalent of Fe(III) (186 
mg, 1.15 mmol) chloride to obtain compound 40 (65% yield). 
Observed m/z value for compound 40: 480.18 (M', -Cl). 
CHN analysis: Calculated (for CHNOLFeCl. 3.8HO) 
C: 53.45%, H, 4.76%, N, 4.80%. Observed: C: 53.27%, H, 
3.95%, N, 4.93%. 
4,4'-DimethoxysalnaphenFe(III) chloride (compound 41): 
The ligand 4,4'-dimethoxysalen (L20, 450 mg, 1.1 mmol) 
was complexed with one equivalent of Fe(III) chloride (194 
mg, 1.2 mmol) to obtain compound 8 (58% yield). Observed 
m/z value for compound 41: 480.25 (M', -Cl). CHN analy 
sis: Calculated (for CHNOFeCl. 1.0HO) C: 58.51%, 
H, 4.15%, N, 5.25%. Observed: C: 58.43%, H, 3.80%, N, 
5.27%. 5,5'-Dimethoxysalnaphen Fe(III) chloride (com 
pound 42): The ligand 5.5'-dimethoxysalen (L21, 400 mg. 
0.94 mmol) was complexed with one equivalent of Fe(III) 
chloride (192 mg, 1.2 mmol) to obtain compound 42 (59% 
yield). Observed m/z value for compound 42: 480.18 (M', 
—Cl). CHN analysis: Calculated (for CHNOFeCl) C: 
60.55%, H, 3.91%, N, 5.43%. Observed: C: 60.07%, H, 
3.73%, N, 5.44%. 
Bis(salicylidene)propanediamine Fe(III) chloride (43):Bis 
(salicylidene) propanediamine ligand was prepared by mix 
ing two equivalent of salicylaldehyde with 1 equivalent of 
1,3-diaminobutane in methanol that resulted in greenish yel 
low precipitate of bis(salicylidene)propane diamine that was 
complexed with 1 equivalent of Fe(III) chloride to obtain 
compound 43. MS (ESI-MS) for Bis(salicylidene)propanedi 
amine Fe(III) chloride: 336.27 (M', -Cl). 
Bis(salicylidene)butanediamine Fe(III) chloride (44): Bis 
(salicylidene)butanediamine ligand was prepared by mixing 
two equivalent of salicylaldehyde with 1 equivalent of 1,4- 
diaminobutane in methanol that resulted in yellow precipitate 
of bis(salicylidene)butanediamine that was complexed with 1 
equivalent of Fe(III) chloride to obtain compound 44. MS 
(ESI-MS) for Bis(salicylidene)butanediamine Fe(III) chlo 
ride: 350.20 (M", Cl). 
Fe(III)-carboxysalphen chloride (compound 45). Two 
equivalents of salicylaldehyde was mixed with one equivalent 
of 3,4-diaminobenzoic acid in methanol that resulted in 
orange colored precipitate of caboxysalphen that was com 
plexed with one equivalent of Fe(III) chloride to obtain com 
pound 45. CHN analysis for compound 45: Calculated (for 
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CHNOFeCl. 1.0HO)C:54.01%, H, 3.24%, N, 6.00%. 
Observed: C: 53.83%, H, 3.48%, N, 5.95%. 
Cell culture: Monolayer of human breast cancer cells 
(MCF-7), colon cancer (CCL228) and breast epithelial cell 
(MCF-10) were grown and maintained in Dulbecco's modi 
fied Eagle's media (DMEM) that was supplemented with heat 
inactivated fetal bovine serum (FBS, 10%), L-glutamine 
(1%) and Penicillin/streptomycin (0.1%)'. Cells were 
cultured and maintained in humidified incubator with 5% 
CO in air at 37° C. Cells were grown on cover slips for 
microscopy studies and in 96 well microtiter plates for cell 
viability and cytotoxicity assays. 
Cell viability assay: Approximately 10,000 MCF-7 cells 
were seeded into each well of a 96 well microtiter plate and 
incubated 24hrs in presence of 150 uL DMEM. An additional 
50 uL DMEM containing required amount of each metallo 
salen to obtain 20 uM final concentrations (in 200 uL final 
volume) in 8 replicate wells were added. Control wells were 
treated with equivalent amount of dimethylsulfoxide 
(DMSO). The viability of the cells was assayed at 24, 48, 72 
and 96 hrs post treatment by using both microscopic obser 
vation and MTT assay. For microscopic observation cells 
were stained with trypan blue for at least 10 minute and 
observed under Differential Interference Contrast (DIC) set 
ting of a fluorescence microscope (Nikon Eclipse TE2000-U. 
Japan). The MTT assay was performed as described previ 
ously. In brief, 20 uL MTT (5 mg/ml in PBS) was added 
into each wells and incubated for 2 hrs under normal growth 
condition to allow the viable cell to convert MTT to formazan. 
Then the media was discarded and formazan crystals were 
dissolved by adding 100 uL of DMSO and incubating 2 hrs 
with continuous shaking. The absorbance of the lysates were 
directly measured at 560 nm using a micro plate reader (Flu 
ostar-omega, BMG Labtech). The absorbance values (which 
are proportional to the viable cell) are plotted as a function of 
time. The studies were repeated twice with 8 replicates each 
time. 
Cytotoxicity assay (ICso measurement): The cytotoxicity 
of Fe(III)-salen and its derivatives was determined by using 
MTT assay as described previously. In brief, approximately 
10,000 MCF-7 cells were seeded into each well of a 96 well 
microtiter plate and incubated 24 hrs in presence of 150 uL 
DMEM. An additional 50 uL DMEM containing required 
amount of each metallo-salen to obtain 0.05 to 60 uM final 
concentration (in 200 uL final volume) in 8 replicate wells 
were added. Control wells were treated with equivalent 
amount of DMSO. After 96 hrs of incubation, 20 uL of MTT 
(5 mg/mL) was added into each well and cell viability was 
assayed by measuring the formazan absorption at 560 nm as 
described above. The absorbance (at 560 nm) values were 
plotted against concentration of metallo-Salens to determine 
the ICs. The studies were repeated twice with 8 replicates 
each time. 
Nuclear fragmentation with DAPI (4,6-diamidino-2-phe 
nylindole) staining: MCF-7 cells were seeded onto a cover 
slip in a 60 mm plate and grown overnight under normal 
growth conditions followed by incubation with 100 uM 
Fe(III)-salen or its derivatives for additional 24 hrs. Control 
cells were treated with equivalent amount of DMSO. Cells 
were fixed with 4%-formaldehyde in PBS for 15 minutes, 
washed twice with PBS, permeabilized with 0.2% Triton 
X-100 in PBS for 5 min. Cells were washed three times with 
cold PBS followed by incubation with DAPI (5ug per slide) 
for 10 minutes at room temperature. DAPI stained cells were 
washed three times with cold PBS, mounted on microscope 
slide with mounting media (Vectashield H-1000, Vector lab) 













Immuno-staining with anti-cytochrome-c: MCF-7 cells 
were seeded onto a cover glass for 24 hrs and Subjected to 
immuno-staining with anti-cytochrome-c antibody as 
described previously. In briefly, cells were fixed for 10 
minutes with 4% formaldehyde, washed twice with PBS, 
permeabilized for 10 minutes using 0.2% Triton X-100 in 
PBS. Cells were blocked with 10% goat serum for 1 hr prior 
to incubation with anti-cytochrome c antibody for additional 
1 hr. Cells were washed thrice with 0.02% tween-20 in cold 
PBS. Secondary antibodies conjugated with FITC were used 
for immuno-fluorescence detections by incubating for 30 
minute. Cells were washed thrice with cold PBS. Nuclear 
counterstaining was performed with DAPI. Immuno-stained 
cells were mounted and observed by using fluorescence 
microscope. 
Caspase-3/7 activity assay: Caspase-3/7 activity was 
assessed using SensoLyteTM Homogenous AMC Caspase-3/7 
Assay Kit (AnaSpec Inc). Briefly, cells were treated with 100 
uM Fe(III) and Mn(III)-salen complexes separately for 0, 8, 
16, and 24 hrs, lysed, and centrifuged (2500 g for 10 min at 4 
C.). The Supernatant was diluted (to 1 Lig/LL of protein) and 
150 uL extract was mixed with 50LL of assay buffer contain 
ing caspase-3/7 substrate, incubated for 15 min at 37° C. and 
then fluorescence intensity (350/440,) was measured 
every 10 min (up to 2 hrs) using FLOUstar Omega micro plate 
reader (BMG labTech). The concentration of activated 
caspase-3/7 was calculated by using calibration curve with 
pure standard. The caspase-3/7 activity was finally expressed 
relative to untreated control cells. 
Application of metallo-Salen complexes in colon cancer 
Xenograft. 
All the animal experiments were carried out using the 
IACUC approved protocol. For examining the efficacies of 
metallo-Salen complexes, the inventors administered selected 
metallo-salen complexes in PBS intraperitoneally on Athy 
mic nude nu/nu mice (Harlan) carrying the colon cancer 
xenografts. In brief, 2x10' human colon cancer cells 
(CCL228 cell in 100 ul of PBS) were injected subcutaneously 
(near the right back limb). Animals were examined daily for 
signs of tumor growth and behavior. Once the tumor size 
reached ~25 mm (2 to 3 weeks after injection of cells) the 
inventors administered the metallo-Salen complexes intrap 
eritoneally (in PBS solution, twice in a week, in three parallel 
replicates). Control mice were injected with equal volume of 
the diluents (PBS) alone. Prior to every new treatment with 
metallo-Salen complexes, bi-dimensional measurements 
were carried out using calipers and cross-sectional area (tu 
mor size) and data were plotted (FIG. 8A). 
The inventors studied the effect of Mn(III)-salen and 
Fe(III)-salen derivatives on the cell viability of cultured 
breast cancer cells MCF-7 in order to investigate the bio 
chemical effects of the derivatives. The cells were incubated 
alone or with 20 uM of each of the metallo-salen derivatives 
separately (compounds 1-45) for varying time periods (0-96 
hrs). The viable cells were quantified using MTT assay and 
the percent of cell survived (relative to the control untreated 
cells) were plotted against time (FIGS. 2A-2F). The DIC 
(Differential Interference Contrast) images of cells under 
light microscope in the absence and presence of each Mn(III)- 
and Fe(III)-salen derivatives are shown on the right panels 
(FIGS. 2A-2F) which shows visual effects of each com 
pounds on MCF-7 cell. The activities of compounds 1-42 on 
cell viability are summarized in Table 1. 
In case of Mn(III)-salen and derivatives several com 
pounds showed significant effects on cell viability (FIGS. 
2A-2F and Table 1). In the salen series with ethylene diamine 
bridge, the parent Mn(III)-salen (compound 1), 3,3'- and 5,5'- 
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dihydroxy Mn(III)-salen (compounds 2 and 4), and all the 
methoxy substituted Mn(III)-salen (3.3-, 4,4'- and 5,5'- 
dimethoxy Mn(III)-salen, compounds 5, 6 and 7 respectively) 
induced significant (40-60%) cell death within 48 hrs post 
treatment in comparison to the control (FIG. 2A/A). In most 
cases, about 80% or more cells were dead by 96 hrs. Interest 
ingly, 4,4'-dihydroxy Mn(III)-salen (compound 3) did not 
have any significant effect on cell viability which suggest that 
the position of the Substituent on Salen ligand play critical role 
in determining their biochemical activities (FIG. 2A/A" and 
Table 1). Notably, although, 4,4'-dihydroxy Mn(III)-salen 
was inactive corresponding 4,4'-dimethoxy Mn(III)-salen 
(compound 6) induced efficient cell death on MCF-7 cell 
(FIG. 2A/A" and Table 1). 
Change in the bridging group from ethylene diamine to 
o-phenylene diamine and 2,3-diamino naphthalene (com 
pounds 1, 8 and 15) increased the cytotoxicity of the metallo 
salens (24 hrs time points, FIGS. 2A/A, 2B/B'and 2C/C). 
Interestingly, the pattern of effects on cell viability of 
hydroxy/methoxy substituted Mn(III)-salphen derivatives 
(compounds 8-14) and hydroxy/methoxy substituted 
Mn(III)-salnaphen derivatives (compounds 15-21) were 
almost similar to corresponding Mn(III)-salen derivatives 
(FIGS. 2 A/A, 2B/B' and 2C/C and Table 1). Notably, 4,4'- 
dihydroxy Mn(III)-salen and salphen derivatives (com 





3,3'-dimethoxy Fe(III)-salen (compound 26) did not show 
any significant effect on cell viability (FIG.2D/D"). Similarly, 
none of the corresponding hydroxy substituted Fe(III)-salen 
derivatives (compounds 23-25) killed MCF-7 cells under 
similar conditions even at 96 hrs of incubation (FIG. 2D/D'). 
In addition, Fe(III)-salen derivatives with longer spacer 
between the dimino bridges, compounds 43 and 44, and 
negatively charged carboxysalphen Fe(III) chloride (com 
pound 45) showed almost no cell killing activity under similar 
condition (data not shown). In case of Fe(III)-salphen and 
Fe(III)-salnaphen derivatives, all the methoxy substituted 
derivatives (compounds 33-35 and 40-42) as well as 3,3'- 
dihydroxy substituted derivatives (compounds 30 and 37) 
were very efficient in inducing cell death on MCF-7 cells 
(FIGS. 2E/E', 2F/F"and Table 1). 
4,4'- and 5,5'-hydroxy substituted Fe(III)-salphens and 
Salnaphens (compounds 31, 32, 38 and 39) did not have any 
effects on cell viability (FIGS. 2E/E, 2F/F"andTable 1). Thus 
changing the bridging group from ethylene diamine to o-phe 
nylene diamine and 2,3-diamino naphthalene made a signifi 
cant difference in terms of reactivities of the methoxy as well 
as hydroxy substituted Fe(III)-salphen and salnaphen deriva 
tives. These observations are in contrast to the Mn(III) com 
plexes which Suggest that not only the Substituent but also the 
nature of the central metal-ion plays a critical role in deter 
mining the cell killing activities of metallo-Salens. 
TABLE 1. 
Summary of cell viability activities. 
Metal Ion 
Mn (III Fe(III 
Bridge En Phen Naphen En Phen Naphen 
Substituent H Y: (1) Y (8) Y (15) Y (22) Y (29) Y (36) 
3,3'-OH Y (2) Y (9) Y (16) N (23) Y (30) Y (37) 
4,4'-OH N (3) N (10) Y (17) N (24) N (31) N (38) 
5,5'-OH Y (4) Y (11) N (18) N (25) N (32) N (39) 
3,3'-OMe Y (5) Y (12) Y (19) N (26) Y (33) Y (40 
4,4'-OMe Y (6) Y (13) Y (20) Y (27) Y (34) Y (41) 
5,5'-OMe Y (7) Y (14) Y (21) Y (28) Y (35) Y (42) 
En: Ethylene diamine, Phen: ortho-phenylene diamine, Naphen: 2,3-diamino naphthalene. 
Yand Nindicates active and inactive compoundsrespectively, The numberinside the parenthesis indicates the 
respective compounds inFIG, 1. 
dihydroxy Mn(III)-salnaphen (compounds 17) was effective 
in inducing cell death in MCF-7 cells (FIGS. 2 A/A, 2B/B' 
and 2C/C'and Table 1). 
Similarly, 5,5-dihydroxy Mn(III)-salen and salphen 
derivatives (compounds 4 and 11) were effective in inducing 
cell death while corresponding 4.5'-dihydroxy Mn(III)-sal 
naphen (compound 18) was inactive (FIGS.2 A/A, 2B/B' and 
2C/C and Table 1). 4,4'-methoxy Mn(III) salphen, the parent 
Mn(III)-salnaphen (compounds 13 and 15) were most effec 
tive on inducing cell death (FIGS. 2A/A, 2B/B' and 2C/C) by 
48 hrs. 
In case of Fe(III)-salen derivatives, the overall pattern of 
cell killing activity was very different in comparison to 
Mn(III)-salen derivatives (FIGS. 2A-2C versus FIGS. 2D-2F 
and Table 1). Among the salen derivatives, only Fe(III)-salen, 
4,4'-, and 5.5'-methoxy substituted Fe(III)-salens (com 
pounds 22, 27, and 28, respectively) were highly effective in 
killing MCF-7 cells in a time dependent manner (FIG. 
2D/D"). 5.5'-dimethoxy Fe(III)-salen (compound 28) killed 
more than 80% of cells in less than 24 hrs, while 4,4'- 
dimethoxy Fe(III)-salen (compound 27) took about 72 hrs to 






The cytotoxicity of Mn(III)- and Fe(III)-salen derivatives 
toward MCF-7 cells were quantified by performing MTT 
assay '' to determine the ICso values as the different 
Mn(III) and Fe(III)-salen derivatives showed differential 
effects on cell viability, the inventors incubated the MCF-7 
cells (in 96 well tissue culture plates) with varying concen 
trations of each of the metallo-salens for 96 hrs and then 
subjected to MTT assay. The concentration of the metal 
complexes at which the conversion of MTT to formazan by 
viable cells is reduced by 50% compared to control cells is 
defined as the ICs. The percent of cell survival relative to the 
control cells were plotted as a function of concentration of the 
metallo-salen derivatives. 
FIGS. 3A-3F represent ICso curves for Mn(III)- and 
Fe(III)-complexes (compounds 1-42) and the ICso values for 
each active compounds are summarized in Table 2. ICs val 
ues for most of the active Mn(III)-complexes lie between 12 
to 23 uM except compounds 2, 4, 11, 14, 16 and 19 whose 
ICso values were higher than 40 uM (FIGS. 3A-3C and Table 
2). Specifically, the parent unsubstituted Mn(III)-salen, sal 
phen and Salnaphen (compounds 1, 8 and 15) and 4,4'- 
dimethoxy substituted Mn(III)-complexes (compounds 6, 13 
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and 20) were the highly effective with ICs values 20.4, 15.0, 
15.5, 12.3, 15.5 and 20.4 uM respectively (Table 2). Similarly, 
compounds 5 (3,3'-dimethoxy Mn(III)-salen), 7 (5.5'- 
dimethoxy Mn(III)-salen), 9 (3,3'-dihydroxy Mn(III)-sal 
phen), and 21 (5.5'-dimethoxy Mn(III)-salnaphen) have ICso 
values below 20 uM (Table 2). 
The ICs values for several Fe(III)-complexes were in the 
nanomolar range which includes 3,3'-dihydroxy Fe(III)-sal 
phen (compound 30, ICs: 330 nM), 4,4'-dimethoxy-Fe(III)- 
salphen (compound 34, ICs: 680 nM), Fe(III)-salnaphen 
(compound 36, ICs: 540 nM), 3,3'-dihydroxy Fe(III)-sal 
naphen (compound 37, ICs: 220 nM) and 4,4'-dimethoxy 
Fe(III)-salnaphen (compound 41, ICs: 530 nM) toward 
MCF-7 cells (Table 2 and FIGS. 3D-3F). Several other 
Fe(III)-compounds ICs values lay between 1-5 uM. These 
results indicate that Fe(III)-salen derivatives have high effi 
ciency in inducing cell death in MCF-7 cells and 3,3'-hydroxy 
and 4,4'-methoxy Substituted Salphen and salnaphen deriva 





antitumor drugs have nano molar ICso values, these com 
pounds have significant potential toward anti-tumor applica 
tions. 
To study the pathway, by which metallo-salen derivatives 
of the present invention induce cell death, the inventors ana 
lyzed the effects of different metallo-salens on the nuclear 
integrity by using fluorescent dye DAPI staining. DAPI is a 
DNA binding dye that has been used extensively for staining 
cell nucleus. Wetreated MCF-7 cells with 100 uMofMn(III)- 
and Fe(III)-salen and their derivatives and incubated for 24 
hrs. Cells were stained with DAPI and visualized under fluo 
rescence microscope. 
The results were in agreement with cell viability data, 
except 4,4'-dihydroxy Mn(III)-salen and salphen and 5.5'- 
dihydroxy Mn(III)-salnaphen derivatives (compounds 3, 10 
and 18), all other remaining Mn(III)-complexes (compounds 
1-2, 4-9, 11-17, 19-21) derivatives induced significant mor 
phological changes with more intense DAPI staining, highly 
condensed and fragmented nucleus in comparison to 
ICso values for different complexes in MCF-7 cells. 
Metal Ion 
Mn(III Fe(III 
Bridge En Phen Naphen En Phen Naphen 
Substituent H (1) (8) (15) (22) (29) (36) 
20.48 1S.O2 15.56 22:45 1.25 O.S4 
3,3'-OH (2) (9) (16) N (23) (30) (37) 
36.9S 17.26 40.28 O.33 O.22 
4,4'-OH N (3) N (10) (17) N(24) N (31) N (38) 
21.38 
5,5'-OH (4) (11) N (18) N (25) N (32) N (39) 
43.13 45.6 
3,3'-OMe (5) (12) (19) N (26) (33) (40) 
17.73 22.18 39.72 4.15 1.5 
4,4'-OMe (6) (13) (20) (27) (34) (41) 
12.31 15.56 20.48 12.4 O.68 O.S3 
5,5'-OMe (7) (14) (21) (28) (35) (42) 
16.15 SS-88 1926 4.56 3.11 1.24 
The number inside the parenthesis indicates the respective compounds in FIG, 1. 
En: Ethylene diamine, Phen: ortho-phenylene diamine, Naphen: 2,3-diamino naphthalene. 
To study the anti-tumor drug potential of Mn(III)- and 
Fe(III)-metallo salen derivatives, the inventors analyzed ICso 
values for the each of the active compounds towards different 
cancer as well as normal cells. The ICs values for different 
active compounds (compounds 1-42) for three different cell 
lines, MCF-7 (breast cancer), CCL228 (colon cancer) and 
MCF-10 (non malignant breast cells), are plotted in the bar 
graph in FIG. 4. Interestingly, most of the active Mn(III)- 
complexes (except compounds 5, 11 and 20) showed signifi 
cant (2-5 fold) selectivity towards breast and colon cancer 
cells (MCF-7 and CCL228) over nonmalignant breast epithe 
lial cells (MCF-10). The preferential apoptotic activities 
toward cancer cells over non cancer cells Suggest the strong 
potential of Mn(III)-salen derivatives toward anti-tumor drug 
application. 
In contrast to Mn(III)-complexes, most of the Fe(III)-salen 
complexes killed normal cells (MCF-10) more preferentially 
over cancer cells except compounds 1 and 27 (FIGS. 4D-4F). 
Compound 27 killed MCF-7 and CCL228 cells about 4 fold 
more efficiently over MCF-10 non malignant cells (FIG. 4D). 
These data Suggest that compound 27 may have strong poten 
tial toward anti-tumor therapeutic application. Notably, as 
several Fe(III)-complexes (such as compounds 30,34, 36,37. 






untreated control cells (FIGS. 5A, 5B and 5C represent 
Mn(III)-Salen, Salphen and Salnaphen derivatives respec 
tively). The effects were more severe on Some cases in com 
parison to others likely because of their efficiencies. The 
nuclear fragmentation and condensation indicates that 
Mn(III)-salen complexes induced apoptotic cell death in 
MCF-7 cells. 
The effects of Fe(III)-salen derivatives (compounds 22-45) 
on nuclear morphology by DAPI staining is shown in FIGS. 
5D-5F. Again, in agreement with cell viability activities, com 
pounds 22, 27-28, 29, 30, 33-35, 36, 37, and 40-42 showed 
significant effects on nuclear morphology and fragmentation 
indicating apoptotic cell death. 
To understand the pathway by which Mn(III)- and Fe(III)- 
salen derivatives induced apoptosis in MCF-7 cells, the 
inventors performed immuno-staining with anti-cytochrome 
c antibody before and after treatment with Mn(III)- and 
Fe(III)-salen derivatives . The cytochrome-c immuno 
stained cells were visualized under fluorescence microscope 
(left panels, FIG. 6) and the corresponding cell nucleus was 
visualized by DAPI staining (right panels, FIG. 6). As 
expected the cytochrome c is localized inside the mitochon 
dria in control untreated cells as evidenced by the speckles 
outside the nucleus (top control panels on each of the FIGS. 
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6A-6F). However, treatment with biochemically active 
Mn(III)-salen derivatives (FIG. 6A), Mn(III)-salphen deriva 
tives (FIG. 6B), Mn(III)-salnaphen derivatives (FIG. 6C), 
Fe(III)-salen derivatives (FIG. 6D), Fe(III)-salphen deriva 
tives (FIG. 6E), and Fe(III)-salnaphen derivatives (FIG. 6F) 
resulted in release of cytochrome c from mitochondria to the 
cytosol as evidenced by its spreading throughout the cell. In 
contrast, inactive compounds showed no significant effect on 
cytochrome c translocation (data not shown). It is well known 
that cytochrome c is normally present inside the mitochondria 
and translocate to cytosol upon changes in mitochondrial 
membrane potential leading to caspase 9 activation during 
apoptotic process. The release of cytochrome c from the 
mitochondria to the cytosol Suggested that Mn(III)- and 
Fe(III)-salen derivatives induced apoptosis in MCF-7 cells 
via mitochondrial pathway. 
To further confirm the apoptotic activities of Mn(III) and 
Fe(III)-salen derivatives of the present invention, the inven 
tors analyzed the activation of caspases-3/7 enzymes. Nota 
bly, to assess the caspase 3/7 activity we used CCL228 cells 
instead of MCF7 as MCF7 cells lack the caspase-3 enzyme. 
The inventors treated cells with 100 uM of Mn (III)-salen or 
Fe(III)-salen complexes separately (compounds 1-42) for 0. 
8, 16 and 24 h and then analyzed the caspase-3/7 activities by 
using a commercial caspase-3/7 assay kit. The caspase activi 
ties of the cells treated with biochemically active Mn(III) and 
Fe(III)-salen derivatives were increased with time with a 
maxima at 16 h post treatment and then declined at higher 
time points likely due to cell death (data not shown). The 
relative caspase-3/7 activities (at 16 h time point) of the 
different metallo-salen derivatives of the present invention in 
CCL228 cells are plotted in FIG. 7. 
As CCL228 cells were used for the caspase assay, the 
inventors compared the caspase activity data of different met 
allo-Salen complexes with their corresponding cytotoxicity 
values (ICs) towards CCL228 cells only. In agreement rela 
tive cytotoxicity values, the active Mn(III) and Fe(III)-salen 
derivatives proportionally induced caspase-3/7 activation 
(FIG.7 and Table 2). These results demonstrated that the level 
of caspase activation is correlated with the level of cytotox 
icity (inversely correlated with the ICs values) which dem 
onstrated that Mn(III)- and Fe(III) salen derivatives induced 
apoptosis via caspase 3/7 activation pathway. 
As several of Mn(III)-salen complexes of the present 
invention showed tumor selective apoptosis in cultured cells, 
the inventors examined the efficacy of a Mn(III)-salen com 
plex in down regulating tumor growth in a human cancer 
Xenograft (implanted in mouse). All the animal experiments 
were carried out using the IACUC approved protocol. 
Animal toxicity: The inventors analyzed the animal toxic 
ity of 3,3'-dimethoxy Mn(III)-salen (compound 6), 3,3'-dihy 
droxy Mn(III)-salphen (compound 9) and 3,3'-dihydroxy 
Mn(III)-salnaphen (compound 16). The inventors intraperi 
toneally administered the Mn(III)-salen complexes (in PBS) 
at three different dozes (5, 10 and 20 mg/kg of mice, 6 weeks 
old normal C57B mice). The mice were treated twice a week 
for 4 weeks. After treatment, sign of toxicity were monitored 
(such as weight loss, mobility), animal behavior and health on 
a daily basis. The results demonstrated that these compounds 
did not have any significant animal toxicity at the doses 
treated (data not shown). All the mice survived without sig 
nificant loss of body weight. 
Xenograft experiment: To test the efficacy in controlling 
the tumor growth, the inventors administered compound 
compounds, 6, 9 and 16, intraperitoneally to six week old 
Athymic nude nu/nu mice carrying the colon cancer 













cell in 100 ul of PBS) were injected subcutaneously (near the 
right back limb). Animals were examined daily for signs of 
tumor growth and behavior. Once the tumor size reached -25 
mm (2 to 3 weeks after injection of cells) the inventors 
administered compounds 6,9, and 16 intraperitoneally (sepa 
rately in PBS solution, twice a week, 10 mg/kg dose). Every 
study was performed in three parallel replicates. Control 
mouse were injected with equal volume of the diluent (PBS) 
alone. Prior to every new treatment with metallo-salens, bi 
dimensional measurements were carried out using calipers 
and cross-sectional area (tumor size) and data were plotted in 
FIG. 8A. 
Application of the compounds 6 and 9 (3,3'-dimethoxy 
Mn(III)-salen and 3,3'-dihydroxy Mn(III)-salphen respec 
tively) resulted in complete arrest of tumor growth while in 
the untreated control (PBS only) or the treatment with com 
pounds 16, tumor size were grown exponentially (FIGS. 8 A 
and 8B). These observations demonstrated that 3,3'- 
dimethoxy Mn(III)-salen (compound 6) and 3,3'-dihydroxy 
Mn(III)-salphen (compound 9) have potential antitumor 
activity in vivo. The results showing the Suppression of tumor 
growth in colon cancer Xenograft upon application of 
Mn(III)-salen complexes of the present invention demon 
strate that they have strong potential for novel anticancer 
therapy, based on these results that apoptotically active 
Mn(III)-salen and Fe(III)-salen complexes of the present 
invention are potential novel anti-neoplastic agents. 
FIGS. 9A and 9B show the structure of some additional 
metallo-Salen complexes with different Substituent groups 
attached. 
The present invention demonstrates that selective Mn(III)- 
and Fe(III)-salen derivatives induce apoptosis in breast and 
colon cancer cells with 2-5 fold preference over normal non 
malignant breast epithelial cells. The position and nature of 
the substituents, central metal ion and the structures of the 
metallo-Salen play critical role in determining their apoptotic 
activities and can be applied to develop novel effective anti 
tumor agents. More importantly, several Mn(III)-Salen com 
plexes of the present invention also Suppressed the tumor 
growth in vivo (in colon cancer Xenografts) indicating a 
strong potential for the Mn(III)- and Fe(III)-salen complexes 
of the present invention as anti-tumor agents. 
It is contemplated that any embodiment discussed in this 
specification can be implemented with respect to any method, 
kit, reagent, or composition of the invention, and vice versa. 
Furthermore, compositions of the invention can be used to 
achieve methods of the invention. 
It will be understood that particular embodiments 
described herein are shown by way of illustration and not as 
limitations of the invention. The principal features of this 
invention can be employed in various embodiments without 
departing from the scope of the invention. Those skilled in the 
art will recognize, or be able to ascertain using no more than 
routine experimentation, numerous equivalents to the specific 
procedures described herein. Such equivalents are considered 
to be within the scope of this invention and are covered by the 
claims. 
All publications and patent applications mentioned in the 
specification are indicative of the level of skill of those skilled 
in the art to which this invention pertains. All publications and 
patent applications are herein incorporated by reference to the 
same extent as if each individual publication or patent appli 
cation was specifically and individually indicated to be incor 
porated by reference. 
The use of the word “a” or “an' when used in conjunction 
with the term “comprising in the claims and/or the specifi 
cation may mean "one.” but it is also consistent with the 
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meaning of “one or more.” “at least one.” and “one or more 
than one.” The use of the term 'or' in the claims is used to 
mean “and/or unless explicitly indicated to refer to alterna 
tives only or the alternatives are mutually exclusive, although 
the disclosure supports a definition that refers to only alter 
natives and “and/or.” Throughout this application, the term 
“about is used to indicate that a value includes the inherent 
variation of error for the device, the method being employed 
to determine the value, or the variation that exists among the 
study Subjects. 
As used in this specification and claim(s), the words "com 
prising (and any form of comprising. Such as “comprise' and 
“comprises”), “having (and any form of having, such as 
“have” and “has'), “including (and any form of including, 
such as “includes and “include’) or “containing (and any 
form of containing, such as “contains' and "contain’) are 
inclusive or open-ended and do not exclude additional, unre 
cited elements or method steps. 
The term “or combinations thereofas used herein refers to 
all permutations and combinations of the listed items preced 
ing the term. For example, A, B, C, or combinations thereof 
is intended to include at least one of A, B, C, AB, AC, BC, or 
ABC, and if order is important in a particular context, also 
BA, CA, CB, CBA, BCA, ACB, BAC, or CAB. Continuing 
with this example, expressly included are combinations that 
contain repeats of one or more item or term, such as BB, 
AAA, MB, BBC, AAABCCCC, CBBAAA, CABABB, and 
so forth. The skilled artisan will understand that typically 
there is no limit on the number of items or terms in any 
combination, unless otherwise apparent from the context. 
All of the compositions and/or methods disclosed and 
claimed herein can be made and executed without undue 
experimentation in light of the present disclosure. While the 
compositions and methods of this invention have been 
described in terms of preferred embodiments, it will be appar 
ent to those of skill in the art that variations may be applied to 
the compositions and/or methods and in the steps or in the 
sequence of steps of the method described herein without 
departing from the concept, spirit and scope of the invention. 
All Such similar substitutes and modifications apparent to 
those skilled in the art are deemed to be within the spirit, 
Scope and concept of the invention as defined by the appended 
claims. 
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What is claimed is: 
1. A pharmaceutical composition comprising 
R6 N R6 S 
Z 
DN / \ 
Rs O No 
R R3 R R4' 
wherein Z is selected from a group comprising —(CH), 













M is a metal selected from a group comprising Mn, 
Mn(II), Mn(III), Fe, Fe(II), Fe(III), Cu, Ni, Hg, Pt. Sc, 
Ti,V, Cr, Co., Zn, Y, Zr, Nb, Mo, Tc, Ru, Rh, Pd, Ag, Cd, 
Lu, Hf, Ta, W. Re, Os, Ir, Pt, and Au, R. and R are 
hydroxyl groups, R. R. R. R. R. and Rare hydro 
gens, and wherein the composition is effective to treat a 
cancer, selected from a lymphoma, a blastoma, a tumor, 
a melanoma, ovarian cancer, breast cancer, non-small 
cell lung cancer, Small cell lung cancer, renal cancer, 
colorectal cancer, pancreatic cancer, gastric cancer, 
bladder cancer, uterine cancer, lymphoma, and prostate 
CaCC. 
2. A pharmaceutical composition comprising 
Z n 
R6 N N R6 
/ \ 
No S Rs O 
wherein Z is selected from a group comprising —(CH), 
—(CH2), —(CH), phenyl, naphthyl and benzoic acid, 
M is a metal selected from a group comprising Mn, 
Mn(II), Mn(III), Fe, Fe(II), Fe(III), Cu, Ni, Hg, Pt. Sc, 
Ti,V, Cr, Co., Zn, Y, Zr, Nb, Mo, Tc, Ru, Rh, Pd, Ag, Cd, 
Lu, Hf, Ta, W. Re, Os, Ir, Pt, and Au, R. and R are 
hydroxyl groups, R. R. Rs. Rs', Re and Rare hydro 
gens, and wherein the composition is effective to treat a 
cancer, selected from a lymphoma, a blastoma, a tumor, 
a melanoma, ovarian cancer, breast cancer, non-small 
cell lung cancer, Small cell lung cancer, renal cancer, 
colorectal cancer, pancreatic cancer, gastric cancer, 
bladder cancer, uterine cancer, lymphoma, and prostate 
CaCC. 





R6 N R6 
Rs O 
wherein Z is selected from a group comprising —(CH), 
—(CH) —(CH), phenyl, naphthyl and benzoic acid, 
M is a metal selected from a group comprising Mn, 
Mn(II), Mn(III), Fe, Fe(II), Fe(III), Cu, Ni, Hg, Pt. Sc, 
Ti,V, Cr, Co., Zn, Y, Zr, Nb, Mo, Tc, Ru, Rh, Pd, Ag, Cd, 
Lu, Hf, Ta, W. Re, Os, Ir, Pt, and Au, Rs and Rs are 
hydroxyl groups, R. R. R. R., 6 and Rare hydro 
gens, and wherein the composition is effective to treat a 
cancer, selected from a lymphoma, a blastoma, a tumor, 
a melanoma, ovarian cancer, breast cancer, non-small 
cell lung cancer, Small cell lung cancer, renal cancer, 
colorectal cancer, pancreatic cancer, gastric cancer, 
bladder cancer, uterine cancer, lymphoma, and prostate 
CaCC. 
4. A method of synthesizing a metallo-Salencompound and 
its derivatives comprising the steps of 
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mixing an aldehyde selected from a group comprising sali 
cylaldehyde, 2,3-dihydroxybenzaldehyde, 2,4-dihy 
droxybenzaldehyde, 2,5-dihydroxybenzaldehyde, 2-hy 
droxy-3-methoxybenzaldehyde, 2-hydroxy-4- 
methoxybenzaldehyde, and 2-hydroxy-5- 
methoxybenzaldehyde and a diamine or a diamino 
derivative selected from a group comprising ethylenedi 
amine, o-phenylenediamine, phenylenediamine, 2,3-di 
aminonaphthalene, 1,3-diaminobutane, 1,4-diaminobu 
tane, and 3,4-diaminobenzoic acid dissolved in an 
organic solvent to form a precipitate; 
filtering the precipitate; 
washing the precipitate with the organic solvent; 
dissolving the precipitate in the organic solvent and mixing 
with an anhydrous metal dissolved in the organic solvent 
to form a liquid reaction mixture; 
heating the liquid reaction mixture with stirring to form the 
metallo-salen compound (I); wherein Z is selected from 
a group comprising —(CH), phenyl, naphthyl, 
—(CH2), —(CH), and benzoic acid; M is a metal 
Selected from a group comprising Fe, Mn, Cu, Ni, Hg, 
Pt, Sc., Ti,V, Cr, Co., Zn, Y, Zr, Nb, Mo, Tc, Ru, Rh, Pd, 
Ag, Cd, Lu, Hf, Ta, W. Re, Os, Ir, Pt, and Au; R and R' 
are independently selected from a hydrogen, a hydroxyl 
group and a methoxy group; R and R are indepen 
dently selected from a hydrogen, a hydroxyl group and a 
methoxy group; Rs and Rs' are independently selected 
from a hydrogen, a hydroxyl group and a methoxy 
group; and R and Rare hydrogens: 
(I) 
precipitating the synthesized metallo-Salen compound (I) 
by cooling the liquid reaction mixture or by adding 
diethyl ether; 
isolating the precipitated metallo-Salen compound (I) by 








recrystallizing the isolated metallo-Salen compound (I) by 
dissolving in the organic solvent. 
5. The method of claim 4, wherein the organic solvent 
comprises methanol, ethanol, acetone, iso-propyl alcohol, 
acetonitrile, benzene, ethyl acetate or any combinations 
thereof. 
6. The method of claim 4, wherein the anhydrous metal is 
in the form of a salt, wherein the salt comprises an anion 
selected from a group comprising a chloride, an acetate, a 
halide, a carbonate, a nitrite, a nitrate, a perchlorate, a Sulfate, 
a Sulfide, and a hydroxide. 
7. A method for treating a cancer in an Subject comprising 
the steps of: 
identifying a subject in need for treatment against the can 
cer, and 
providing a therapeutically effective amount of a compo 
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wherein Z is selected from a group comprising —(CH), 
phenyl, naphthyl, -(CH2), —(CH), and benzoic 
acid; M is a metal selected from a group comprising Fe, 
Mn, Cu, Ni, Hg, Pt, Sc., Ti,V, Cr, Co., Zn, Y, Zr, Nb, Mo, 
Tc, Ru, Rh, Pd, Ag, Cd, Lu, Hf, Ta, W. Re, Os, Ir, Pt, and 
Au; R and Rare independently selected from a hydro 
gen, a hydroxyl group and a methoxy group; R and R' 
are independently selected from a hydrogen, a hydroxyl 
group and a methoxy group; Rs and Rs' are indepen 
dently selected from a hydrogen, a hydroxyl group and a 
methoxy group; and R and Rare hydrogens. 
8. The method of claim 7, wherein the cancer comprises a 
melanoma, ovarian cancer, breast cancer, non-Small cell lung 
cancer, Small cell lung cancer, renal cancer, colorectal cancer, 
pancreatic cancer, gastric cancer, bladder cancer, uterine can 
cer, lymphoma, and prostate cancer. 
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